Funder: Pershing Square Sohn Cancer Research Alliance
Due Dates: November 4, 2024 (Letter of Intent) | February 26, 2025 (Finalist presentations) | May 22, 2025 (Award Dinner)
Funding Amounts: $750,000 total ($250,000/year for 3 years; up to 10% indirect costs included)
Summary: Supports early-to-mid-career investigators in the U.S. pursuing innovative, high-risk research to advance understanding and treatment of neurodegenerative diseases.
Key Information: Applicants must have 1–10 years of independent research experience and hold a faculty or equivalent appointment at a U.S. academic or nonprofit research institution.